Literature DB >> 31741619

Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.

Dominik F Draxler1, Lisa M Wutzlhofer1, Georg Slavka1, Wolfgang Hübl1, Heinz Ludwig2, Martin Schreder2, John Reynolds3, Martin Willheim1.   

Abstract

Increasing interest has been expressed for flow cytometric immunophenotyping for diagnosis and monitoring in plasma cell dyscrasias over the last decades. The aim of this investigation was to compare the expression strength of various cell surface markers used traditionally or currently under investigation on normal and abnormal PC populations. We enrolled 295 consecutive patients undergoing bone marrow aspiration in the workup of monoclonal gammopathies, selecting 54 normal and 241 abnormal PC populations via flow cytometry to characterize the expression of CD45, CD38, CD138, CD19, CD56, CD20, CD27, CD28, CD81, CD117 and CD200 on the cell surface of PCs. We observed significant differences in the expression strength of all assessed markers between normal and abnormal PC populations in all markers except for CD20. While none of them was conclusive on its own, the combination of CD81 positivity and CD117 negativity was present in 98.1% of normal PC populations tested. In contrast, particularly CD117 positivity, but also CD81 negativity was indicative of an abnormal PC phenotype. Our results highlight the descriptive value of CD81 and CD117 for the allocation of bone marrow PCs to a normal or abnormal phenotype. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  FACS; Flow cytometry; Multiple myeloma; Plasma cell dyscrasias; Plasma cells

Year:  2019        PMID: 31741619      PMCID: PMC6825118          DOI: 10.1007/s12288-019-01105-w

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  42 in total

1.  CD200 is a new prognostic factor in multiple myeloma.

Authors:  Jerome Moreaux; Dirk Hose; Thierry Reme; Eric Jourdan; Michael Hundemer; Eric Legouffe; Philippe Moine; Philippe Bourin; Marion Moos; Jill Corre; Thomas Möhler; John De Vos; Jean Francois Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

2.  Lack of CD27 in myeloma delineates different presentation and outcome.

Authors:  Philippe Moreau; Nelly Robillard; Gaétan Jégo; Catherine Pellat; Steven Le Gouill; Soraya Thoumi; Hervé Avet-Loiseau; Jean-Luc Harousseau; Régis Bataille
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

3.  CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease.

Authors:  Jeroen E J Guikema; Sjoerd Hovenga; Edo Vellenga; Jelle J Conradie; Wayel H Abdulahad; Roelof Bekkema; Jan W Smit; Fenghuang Zhan; John Shaughnessy; Nicolaas A Bos
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

4.  Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation.

Authors:  S Barrena; J Almeida; M Yunta; A López; N Fernández-Mosteirín; M Giralt; M Romero; L Perdiguer; M Delgado; A Orfao; P A Lazo
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

5.  Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells.

Authors:  M Ocqueteau; A Orfao; R García-Sanz; J Almeida; M Gonzalez; J F San Miguel
Journal:  Br J Haematol       Date:  1996-12       Impact factor: 6.998

6.  Phenotypic difference of normal plasma cells from mature myeloma cells.

Authors:  H Harada; M M Kawano; N Huang; Y Harada; K Iwato; O Tanabe; H Tanaka; A Sakai; H Asaoku; A Kuramoto
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

7.  CD28, a marker associated with tumoral expansion in multiple myeloma.

Authors:  N Robillard; G Jego; C Pellat-Deceunynck; D Pineau; D Puthier; M P Mellerin; S Barillé; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

Review 8.  Immunophenotyping of selected hematologic disorders--focus on lymphoproliferative disorders with more than one malignant cell population.

Authors:  A Porwit
Journal:  Int J Lab Hematol       Date:  2013-06       Impact factor: 2.877

Review 9.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

10.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Authors:  Andy C Rawstron; Alberto Orfao; Meral Beksac; Ludmila Bezdickova; Rik A Brooimans; Horia Bumbea; Klara Dalva; Gwenny Fuhler; Jan Gratama; Dirk Hose; Lucie Kovarova; Michael Lioznov; Gema Mateo; Ricardo Morilla; Anne K Mylin; Paola Omedé; Catherine Pellat-Deceunynck; Martin Perez Andres; Maria Petrucci; Marina Ruggeri; Grzegorz Rymkiewicz; Alexander Schmitz; Martin Schreder; Carine Seynaeve; Martin Spacek; Ruth M de Tute; Els Van Valckenborgh; Nicky Weston-Bell; Roger G Owen; Jesús F San Miguel; Pieter Sonneveld; Hans E Johnsen
Journal:  Haematologica       Date:  2008-02-11       Impact factor: 9.941

View more
  1 in total

1.  Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry.

Authors:  R Gupta; P Gupta; K Rahman; S Biswas; D Chandra; M K Singh; M K Sarkar; A Gupta; S Nityanand
Journal:  Indian J Hematol Blood Transfus       Date:  2021-08-10       Impact factor: 0.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.